F. Hoffmann-La Roche AG / Tensha Therapeutics, Inc.

NUT Midline Carcinoma & Hematologic Malignancies (AML/MDS)

Disease Overview

NUT midline carcinoma is an ultra-rare, highly aggressive squamous cell cancer driven by NUTM1 gene rearrangement (typically BRD4-NUT fusion), affecting midline structures of head/neck/thorax with no standard therapy and median survival of 6-10 months. AML is a heterogeneous bone-marrow cancer with 22,010 estimated US new cases in 2025 and historically poor 5-year survival in older patients.

Competitive Landscape

BET (bromodomain/extra-terminal) inhibitors emerged as a hot epigenetic class around 2014-2016, with NMC as the lead indication because BRD4-NUT fusions provide direct genetic rationale. Tensha's TEN-010 competed against Constellation Pharmaceuticals' CPI-0610 (later acquired by MorphoSys), GSK's GSK525762 (molibresib), Incyte/AbbVie's ABBV-075 (mivebresib), and Resverlogix's apabetalone (cardiovascular). The class has been plagued by narrow therapeutic indices (thrombocytopenia, GI toxicity) and modest single-agent activity outside NMC. Roche's $535M Tensha buyout — $115M upfront, $420M milestones — was framed by James Bradner of Dana-Farber as moving TEN-010 'into the pipeline of a world leader'. TEN-010 was renamed RG6146 and continued in early hematology and solid tumor trials but did not advance to registration. As of 2025, no BET inhibitor is FDA-approved, and NMC remains without a standard of care, validated only retrospectively as a difficult class.